E. Leray, J. Yaouanq, L. Page, and E. , Evidence for a two-stage disability progression in multiple sclerosis, Brain, vol.133, issue.7, pp.1900-1913, 2010.
DOI : 10.1093/brain/awq076

H. Miller, D. Newell, and A. Ridley, Multiple sclerosis: treatment of acute exacerbations with corticotrophin (ACTH), Lancet, vol.2, pp.1120-1142, 1961.

L. Durelli, D. Cocito, and A. Riccio, High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations, Neurology, vol.36, issue.2, pp.238-281, 1986.
DOI : 10.1212/WNL.36.2.238

N. Milligan, R. Newcombe, and D. Compston, A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects., Journal of Neurology, Neurosurgery & Psychiatry, vol.50, issue.5, pp.511-527, 1987.
DOI : 10.1136/jnnp.50.5.511

. After-optic-neuritis, Experience of the Optic Neuritis Treatment Trial, Ophthalmology, vol.101, pp.1771-78, 1994.

R. Beck and J. Trobe, What We Have Learned from the Optic Neuritis Treatment Trial, Ophthalmology, vol.102, issue.10, pp.1504-1512, 1995.
DOI : 10.1016/S0161-6420(95)30839-1

R. Beck, Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis, The Lancet, vol.349, issue.9066, p.1696, 1997.
DOI : 10.1016/S0140-6736(05)62663-3

A. Citterio, L. Mantia, L. Ciucci, and G. , Corticosteroids or ACTH for acute exacerbations in multiple sclerosis
DOI : 10.1002/14651858.CD001331

F. Sellebjerg, J. Frederiksen, P. Nielsen, and J. Olesen, Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS, Neurology, vol.51, issue.2, pp.529-563, 1998.
DOI : 10.1212/WNL.51.2.529

F. Sellebjerg, H. Nielsen, J. Frederiksen, and J. Olesen, A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis, Neurology, vol.52, issue.7, pp.1479-84, 1999.
DOI : 10.1212/WNL.52.7.1479

J. Burton, O. Connor, P. Hohol, and M. , Oral versus intravenous steroids for treatment of relapses in multiple sclerosis

D. Barnes, R. Hughes, and R. Morris, Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis, The Lancet, vol.349, issue.9056, pp.902-908, 1997.
DOI : 10.1016/S0140-6736(96)06453-7

C. 15-ramo-tello, L. Grau-lopez, and M. Tintore, A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS, Multiple Sclerosis Journal, vol.130, issue.6, pp.717-725, 2014.
DOI : 10.1136/jnnp.55.6.450

V. Martinelli, A. Pulizzi, and P. Annovazzi, A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS, Neurology, vol.73, issue.22, pp.1842-1890, 2009.
DOI : 10.1212/WNL.0b013e3181c3fd5b

S. Morrow, C. Stoian, J. Dmitrovic, S. Chan, and L. Metz, The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis, Neurology, vol.63, issue.6, pp.1079-80, 2004.
DOI : 10.1212/01.WNL.0000138572.82125.F5

F. Lublin, S. Reingold, and J. Cohen, Defining the clinical course of multiple sclerosis: The 2013 revisions, Neurology, vol.83, issue.3, pp.278-86, 2014.
DOI : 10.1212/WNL.0000000000000560

C. Polman, S. Reingold, and G. Edan, Diagnostic criteria for multiple sclerosis: 2005 revisions to the ???McDonald Criteria???, Annals of Neurology, vol.6, issue.6
DOI : 10.1002/ana.20703

J. Kurtzke, Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), 21 International Conference on Harmonisation, pp.1444-52, 1983.
DOI : 10.1212/WNL.33.11.1444